ERBB2 and breast cancer: HER2+ breast cancer is mainly treated with combinations including taxane-based chemotherapy plus trastuzumab (272), pertuzumab (273), the tyrosine kinase inhibitor lapatinib (274, 275), or combinations thereof (266, 276).